Am. J. Respir. Cell Mol. Biol., Volume 18, Number 2, February, 1998 197-204

Platelet-activating Factor Plays a Pivotal Role in the Induction of Experimental Lung Injury

Jadwiga M. Miotla, Peter K. Jeffery, and Paul G. Hellewell

Applied Pharmacology and Lung Pathology, Imperial College School of Medicine at the National Heart and Lung Institute, London, United Kingdom

We have previously described a model of acute lung injury in the mouse in which intravenous administration of lipopolysaccharide (LPS) results in a marked sequestration of neutrophils in the pulmonary microvasculature, although this by itself was not sufficient to induce injury. If the sequestered neutrophils were exposed to zymosan, then a striking increase in pulmonary vascular permeability to albumin was found, suggesting that sequestered neutrophils may produce one or more mediators capable of acting directly on the capillary endothelium. Because activated neutrophils are known to release platelet-activating factor (PAF), we hypothesized that PAF produced locally within the pulmonary capillaries may be the mediator involved. Treatment of mice with the PAF antagonist UK-74,505 prior to administration of zymosan alone or combined LPS and zymosan resulted in a substantial attenuation of lung injury, as measured by the accumulation of extravascular ¹²⁵I-labeled human serum albumin. UK-74,505 had no effect on neutrophil sequestration as measured by myeloperoxidase activity in whole lung tissue and as assessed by light microscopy. Administration of UK-74,505 after LPS, but before zymosan, was also effective at inhibiting lung injury but again, neutrophil sequestration was unaffected. In contrast, UK-74,505 had no effect on cobra venom factor-induced lung injury and neutrophil sequestration. These data suggest that PAF production is involved in the increases in pulmonary vascular permeability, but not in the sequestration of neutrophils, induced by zymosan alone or by combined LPS and zymosan treatment. Early treatment with PAF antagonists may be beneficial in preventing the development of acute lung injury in humans.

This article has been cited by other articles:

				K. F. van der Sluijs, L. J. R. van Elden, M. Nijhuis, R. Schuurman, S. Florquin, T. Shimizu, S. Ishii, H. M. Jansen, R. Lutter, and T. van der Poll Involvement of the platelet-activating factor receptor in host defense against Streptococcus pneumoniae during postinfluenza pneumonia Am J Physiol Lung Cell Mol Physiol, January 1, 2006; 290(1): L194 - L199. [Abstract] [Full Text] [PDF]

				J. H. Tinsley, J. W. Breslin, N. R. Teasdale, and S. Y. Yuan PKC-dependent, burn-induced adherens junction reorganization and barrier dysfunction in pulmonary microvascular endothelial cells Am J Physiol Lung Cell Mol Physiol, August 1, 2005; 289(2): L217 - L223. [Abstract] [Full Text] [PDF]

				B. B. Rubin, G. P. Downey, A. Koh, N. Degousee, F. Ghomashchi, L. Nallan, E. Stefanski, D. W. Harkin, C. Sun, B. P. Smart, et al. Cytosolic Phospholipase A2-{alpha} Is Necessary for Platelet-activating Factor Biosynthesis, Efficient Neutrophil-mediated Bacterial Killing, and the Innate Immune Response to Pulmonary Infection: cPLA2-{alpha} DOES NOT REGULATE NEUTROPHIL NADPH OXIDASE ACTIVITY J. Biol. Chem., March 4, 2005; 280(9): 7519 - 7529. [Abstract] [Full Text] [PDF]

				J. H. Tinsley, N. R. Teasdale, and S. Y. Yuan Myosin light chain phosphorylation and pulmonary endothelial cell hyperpermeability in burns Am J Physiol Lung Cell Mol Physiol, April 1, 2004; 286(4): L841 - L847. [Abstract] [Full Text] [PDF]

				J. Watanabe, G. K. Marathe, P. O. Neilsen, A. S. Weyrich, K. A. Harrison, R. C. Murphy, G. A. Zimmerman, and T. M. McIntyre Endotoxins Stimulate Neutrophil Adhesion Followed by Synthesis and Release of Platelet-activating Factor in Microparticles J. Biol. Chem., August 29, 2003; 278(35): 33161 - 33168. [Abstract] [Full Text] [PDF]

				A. J. Tonks, A. Tonks, R. H. K. Morris, K. P. Jones, and S. K. Jackson Regulation of platelet-activating factor synthesis in human monocytes by dipalmitoyl phosphatidylcholine J. Leukoc. Biol., July 1, 2003; 74(1): 95 - 101. [Abstract] [Full Text] [PDF]

				M. de Perrot, M. Liu, T. K. Waddell, and S. Keshavjee Ischemia-Reperfusion-induced Lung Injury Am. J. Respir. Crit. Care Med., February 15, 2003; 167(4): 490 - 511. [Abstract] [Full Text] [PDF]

				G. Asimakopoulos, E. A. Lidington, J. Mason, D. O. Haskard, K. M. Taylor, and R. C. Landis Effect of aprotinin on endothelial cell activation J. Thorac. Cardiovasc. Surg., July 1, 2001; 122(1): 123 - 128. [Abstract] [Full Text] [PDF]

				G. Asimakopoulos, R. Thompson, S. Nourshargh, E. A. Lidington, J. C. Mason, C. P. Ratnatunga, D. O. Haskard, K. M. Taylor, and R. C. Landis An anti-inflammatory property of aprotinin detected at the level of leukocyte extravasation J. Thorac. Cardiovasc. Surg., August 1, 2000; 120(2): 361 - 369. [Abstract] [Full Text] [PDF]

				F. Rose, L. Kiss, F. Grimminger, K. Mayer, U. Grandel, W. Seeger, E. Bieniek, and U. Sibelius E. coli hemolysin-induced lipid mediator metabolism in alveolar macrophages: impact of eicosapentaenoic acid Am J Physiol Lung Cell Mol Physiol, July 1, 2000; 279(1): L100 - L109. [Abstract] [Full Text] [PDF]

				R. J. Kaner, J. V. Ladetto, R. Singh, N. Fukuda, M. A. Matthay, and R. G. Crystal Lung Overexpression of the Vascular Endothelial Growth Factor Gene Induces Pulmonary Edema Am. J. Respir. Cell Mol. Biol., June 1, 2000; 22(6): 657 - 664. [Abstract] [Full Text]

				D. M. Stafforini, L. W. Tjoelker, S. P. A. McCormick, D. Vaitkus, T. M. McIntyre, P. W. Gray, S. G. Young, and S. M. Prescott Molecular Basis of the Interaction between Plasma Platelet-activating Factor Acetylhydrolase and Low Density Lipoprotein J. Biol. Chem., March 12, 1999; 274(11): 7018 - 7024. [Abstract] [Full Text] [PDF]

				J. M. Miotla, M. M. Teixeira, and P. G. Hellewell Suppression of Acute Lung Injury in Mice by an Inhibitor of Phosphodiesterase Type 4  Am. J. Respir. Cell Mol. Biol., March 1, 1998; 18(3): 411 - 420. [Abstract] [Full Text]